Approval of the Investigational New Drug (IND) by the U.S. Food and Drug Administration (FDA) has opened the door for the ISM8969 clinical trial in the United States. This Phase I study is set to assess the safety, tolerability, and pharmacokinetics of ISM8969, a new oral therapeutic. The approval marks an important milestone, allowing the trial to move forward and potentially benefit patients.